摘要
目的探讨血清中ＣＡ１９－９的测定在消化道恶性肿瘤的诊断及动态观察中的价值。方法用微粒子酶免疫法对５０例胰腺癌、３４例肝癌、２７例肠癌及一些消化道良性肿瘤患者血清ＣＡ１９－９进行测定，并对胰腺癌、肝癌、肠癌转移组和未转移组及治疗前后血清ＣＡ１９－９的水平进行比较。结果胰腺癌、肝癌、肠癌患者血清中ＣＡ１９－９的水平分别为１７５．３±９７．５４、１５４．３±８９．２５、１１６．４±１０１．３２Ｕ／ｍｌ，明显高于正常对照组的１５．４±９．７１Ｕ／ｍｌ（Ｐ＜０．０１），且转移组的水平明显高于未转移组（Ｐ＜０．０５）。施行根治术后，病人血清ＣＡ１９－９的水平显著下降（Ｐ＜０．０５），而采用姑息术、化疗或放疗的患者血清ＣＡ１９－９水平虽有所下降，但仍显著高于正常。结论血清ＣＡ１９－９测定对消化道恶性肿瘤，尤其是胰腺癌、肝癌和肠癌的诊断有重要价值，且对这些疾病的疗效监测和预后评估起到积极作用。
Objectives To investigate the value of serum CA19-9 in the diagnosis and dynamic change in the therapy of maliglant gastroenteric tumor.Methods The level of serum CA19-9 was studied in 45 patients with pancreatic cancer、34 patients with liver cancer、27 patients with intestinal cancer and some other patients with benign gastroentric disease.The level of serum CA19-9 for those patients suffering from pancreatic、liver or intestinal cancer n metastasis group or non-metastasis was compared and the dynamic change during the therapy was studied,using microparticle enzyme-immunoassay(MEIA).Results The level of serum CA19-9 for those patients with pancreatic cancer、liver cancer or intestinal cancer was 175.3±97.54、154.3±89.25、116.4±101.32U/ml respectively.All the level was higher than that in normal human being ( P <0.05) and the level of serum CA19-9 in metastasis group was higher than that in non-metastasis group ( P <0.05).After effecting a radical cure,the level of serum CA19-9 reduced significantly,whereas after radiotherapy、chemotherapy or appeasement therapy,the level reduced weakly,but it was higher than that in normal group yet.Conclusions Serum CA19-9 is a good marker in diagnosis of maliglant gastroenteric tumor,especially in pancreatic、liver or intestinal cancer,and it′s change may be useful for the monitoring of disease progression and response to therapy.
出处
《宁夏医学杂志》
CAS
1999年第1期6-7,共2页
Ningxia Medical Journal
